BioCentury | Feb 15, 2019
Company News

Samsung Bioepis partners with AffaMed, expands biosimilar development in China

...Samsung Bioepis Co. Ltd., Incheon, South Korea AffaMed Therapeutics, Shanghai, China Business: Cancer, hematology, autoimmune Hongjiang Li biosimilar eculizumab...
BioCentury | Jun 22, 2018
Clinical News

Antibodies neutralize Catalyst's Factor IX variant

...International Society of Thrombosis and Haemostasis (ISTH) meeting in Dublin on July 18. Catalyst's partner Isu Abxis...
...Status: Phase I/II data Milestone: Additional Phase I/II data (7/18/18) Jennie Walters CB 2679d, FIX-NG, ISU 304 Catalyst Biosciences Isu Abxis...
BioCentury | Jun 18, 2018
Clinical News

Antibodies neutralize Catalyst's Factor IX variant, crater stock

...International Society of Thrombosis and Haemostasis (ISTH) meeting in Dublin on July 18. Catalyst's partner Isu Abxis...
...commercialization rights. Isu Abxis fell KrW590 to KrW9,510 on Monday. Jennie Walters CB 2679d, FIX-NG, ISU 304 Catalyst Biosciences Inc. Isu Abxis...
BioCentury | Oct 3, 2016
Finance

Dressed in black

...in preclinical development to treat hemophilia B. The next-generation Factor IX variant is partnered with Isu Abxis...
BioCentury | Sep 19, 2016
Company News

Catalyst Biosciences hematology news

...Factor IX variant, is in preclinical development to treat hemophilia B. In 2013, Catalyst and Isu Abxis...
...Phase I testing, Isu Abxis retains rights to commercialize the product in South Korea. Catalyst expects Isu Abxis...
BioCentury | Apr 6, 2015
Company News

Catalyst Biosciences, Targacept deal

...hemophilia B, with Phase I testing slated for next year. CB 2679d is partnered with Isu Abxis...
BioCentury | Feb 13, 2014
Targets & Mechanisms

A RIPping target in Gaucher's disease

...reduction therapy (SRT) Marketed Genzyme; Sanofi Cerdelga eliglustat tartrate Glucosylceramide synthase inhibitor SRT Phase III Isu Abxis...
BioCentury | Oct 14, 2013
Finance

Highlights of weekly biotech stock moves

...planning a Phase II trial of veltuzumab in systemic lupus erythematosis (SLE) (see B5) . Isu Abxis...
...I, after which it will be responsible for development of FIX-NG ( CB 2679d ). Isu Abxis...
BioCentury | Oct 14, 2013
Company News

Catalyst Biosciences, Isu Abxis deal

...Factor IX protein is in preclinical testing, with Phase I slated to start in 2015. Isu Abxis...
...develop FIX-NG through Phase I testing and will receive an undisclosed percentage of potential revenue. Isu Abxis...
...development of FIX-NG after Phase I testing. Catalyst Biosciences Inc. , South San Francisco, Calif. Isu Abxis...
BioCentury | Oct 9, 2013
Company News

Catalyst, Isu Abxis partner for Catalyst's Factor IX

...Catalyst Biosciences Inc. (South San Francisco, Calif.) and Isu Abxis Co. Ltd. (KOSDAQ:086890) partnered to develop Catalyst's...
...Factor IX protein is in preclinical testing, with Phase I slated to start in 2015. Isu Abxis...
...develop FIX-NG through Phase I testing and will receive an undisclosed percentage of potential revenue. Isu Abxis...
Items per page:
1 - 10 of 12